Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in frontline treatment of advanced classical Hodgkin lymphoma (window study)
2018-002227-42Phase 2Unknown
- Sponsor
- University College London
- Start
- Nov 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in classical Hodgkin lymphoma (cHL), sponsored by University College London. Primary endpoint: Overall response rate after avelumab window. Status: unknown.
02
Drugs
avelumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2018-002227-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002227-42.